Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results